Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other financing activities (2016 - 2022)

Historic Other financing activities for Cumberland Pharmaceuticals (CPIX) over the last 14 years, with Q1 2022 value amounting to -$370464.0.

  • Cumberland Pharmaceuticals' Other financing activities fell 23229.91% to -$370464.0 in Q1 2022 from the same period last year, while for Mar 2022 it was -$650484.0, marking a year-over-year decrease of 40985.96%. This contributed to the annual value of $135405.0 for FY2020, which is 8645.95% down from last year.
  • According to the latest figures from Q1 2022, Cumberland Pharmaceuticals' Other financing activities is -$370464.0, which was down 23229.91% from -$632646.0 recorded in Q4 2021.
  • Cumberland Pharmaceuticals' Other financing activities' 5-year high stood at $1.0 million during Q3 2019, with a 5-year trough of -$670985.0 in Q4 2020.
  • For the 5-year period, Cumberland Pharmaceuticals' Other financing activities averaged around $169073.1, with its median value being $248108.0 (2018).
  • Its Other financing activities has fluctuated over the past 5 years, first crashed by 31072.13% in 2020, then skyrocketed by 18139.46% in 2021.
  • Cumberland Pharmaceuticals' Other financing activities (Quarter) stood at $135202.0 in 2018, then skyrocketed by 135.52% to $318423.0 in 2019, then plummeted by 310.72% to -$670985.0 in 2020, then increased by 5.71% to -$632646.0 in 2021, then surged by 41.44% to -$370464.0 in 2022.
  • Its Other financing activities was -$370464.0 in Q1 2022, compared to -$632646.0 in Q4 2021 and $452536.0 in Q3 2021.